Format

Send to

Choose Destination
Oncotarget. 2016 Aug 23;7(34):55128-55140. doi: 10.18632/oncotarget.10422.

MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma.

Author information

1
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
2
Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
3
Department of Informatics, University of Oslo, Oslo, Norway.

Abstract

The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway is frequently hyper-activated upon vemurafenib treatment of melanoma. We have here investigated the relationship between SRY-box 10 (SOX10), forkhead box 3 (FOXD3) and microphthalmia-associated transcription factor (MITF) in the regulation of the receptor tyrosine-protein kinase ERBB3, and its cognate ligand neuregulin 1-beta (NRG1-beta). We found that both NRG1-beta and ERBB3 mRNA levels were elevated as a consequence of MITF depletion, induced by either vemurafenib or MITF small interfering RNA (siRNA) treatment. Elevation of ERBB3 receptor expression after MITF depletion caused increased activation of the PI3K pathway in the presence of NRG1-beta ligand. Together, our results suggest that MITF may play a role in the development of acquired drug resistance through hyper-activation of the PI3K pathway.

KEYWORDS:

ERBB3; MITF; NRG1-beta; PI3K signaling; melanoma

PMID:
27391157
PMCID:
PMC5342406
DOI:
10.18632/oncotarget.10422
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center